ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,689,307 | -13.4% | 67,065 | 0.0% | 0.10% | -12.8% |
| Q4 2022 | $3,107,121 | +11.9% | 67,065 | 0.0% | 0.12% | +2.6% |
| Q3 2022 | $2,777,000 | +4.9% | 67,065 | +51.2% | 0.11% | +9.6% |
| Q2 2022 | $2,647,000 | -74.1% | 44,365 | -68.5% | 0.10% | -71.0% |
| Q1 2022 | $10,220,000 | -13.6% | 140,726 | 0.0% | 0.36% | -5.8% |
| Q4 2021 | $11,834,000 | -6.8% | 140,726 | 0.0% | 0.38% | -6.8% |
| Q3 2021 | $12,692,000 | -1.1% | 140,726 | +4.6% | 0.41% | -1.9% |
| Q2 2021 | $12,833,000 | +15.6% | 134,590 | +38.1% | 0.42% | +9.2% |
| Q1 2021 | $11,099,000 | -17.7% | 97,480 | 0.0% | 0.38% | -19.4% |
| Q4 2020 | $13,494,000 | +68.4% | 97,480 | 0.0% | 0.47% | +58.0% |
| Q3 2020 | $8,012,000 | +5.1% | 97,480 | 0.0% | 0.30% | +3.4% |
| Q2 2020 | $7,625,000 | +76.1% | 97,480 | 0.0% | 0.29% | +48.0% |
| Q1 2020 | $4,331,000 | +4.0% | 97,480 | 0.0% | 0.20% | +24.8% |
| Q4 2019 | $4,163,000 | -0.2% | 97,480 | 0.0% | 0.16% | -13.7% |
| Q3 2019 | $4,170,000 | +70.7% | 97,480 | +153.3% | 0.18% | +82.0% |
| Q2 2019 | $2,443,000 | -54.2% | 38,480 | -50.0% | 0.10% | -53.9% |
| Q1 2019 | $5,338,000 | +59.5% | 76,958 | 0.0% | 0.22% | +51.7% |
| Q4 2018 | $3,346,000 | -43.0% | 76,958 | 0.0% | 0.14% | -32.9% |
| Q3 2018 | $5,875,000 | -0.7% | 76,958 | 0.0% | 0.21% | -4.9% |
| Q2 2018 | $5,916,000 | -21.9% | 76,958 | -48.2% | 0.22% | -24.1% |
| Q1 2018 | $7,575,000 | +9.9% | 148,558 | 0.0% | 0.30% | +10.9% |
| Q4 2017 | $6,890,000 | -12.9% | 148,558 | 0.0% | 0.27% | -6.0% |
| Q3 2017 | $7,912,000 | +0.1% | 148,558 | +16.7% | 0.28% | -3.4% |
| Q2 2017 | $7,907,000 | +32.0% | 127,308 | +44.0% | 0.29% | +26.3% |
| Q1 2017 | $5,992,000 | -3.6% | 88,400 | 0.0% | 0.23% | -12.5% |
| Q4 2016 | $6,215,000 | -0.9% | 88,400 | 0.0% | 0.26% | +10.0% |
| Q3 2016 | $6,271,000 | +45.0% | 88,400 | 0.0% | 0.24% | +36.9% |
| Q2 2016 | $4,324,000 | -22.7% | 88,400 | 0.0% | 0.18% | -26.1% |
| Q1 2016 | $5,597,000 | -43.6% | 88,400 | 0.0% | 0.24% | -33.9% |
| Q4 2015 | $9,917,000 | +16.5% | 88,400 | 0.0% | 0.36% | +17.6% |
| Q3 2015 | $8,514,000 | +38.6% | 88,400 | +47.3% | 0.31% | +37.8% |
| Q2 2015 | $6,143,000 | – | 60,000 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |